Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption

• Published in: PloS one Vol. 10; no. 7; p. e0126113
• Main Authors: Bergen, Andrew W., Michel, Martha, Nishita, Denise, Krasnow, Ruth, Javitz, Harold S., Conneely, Karen N., Lessov-Schlaggar, Christina N., Hops, Hyman, Zhu, Andy Z. X., Baurley, James W., McClure, Jennifer B., Hall, Sharon M., Baker, Timothy B., Conti, David V., Benowitz, Neal L., Lerman, Caryn, Tyndale, Rachel F., Swan, Gary E.
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 01.07.2015; Public Library of Science (PLoS)
• Subjects: Abstinence; Adult; Alleles; Analysis; Biomarkers; Biopharmaceuticals; Cancer; Cancer prevention; Cancer therapies; Cigarettes; Clinical trials; Compounds; Cotinine; Cytochrome P-450; Cytochrome P-450 CYP2A6 - genetics; Cytochrome P-450 CYP2A6 - metabolism; Deoxyribonucleic acid; DNA; Drug addiction; Drug therapy; Enzymes; Epidemiology; Female; Genes; Genetic Association Studies; Genetic testing; Genetic Variation; Genomes; Genomics; Health care; Health risks; Human subjects; Humans; Laboratories; Lung cancer; Lung diseases; Male; Medical research; Medical treatment; Mental health; Meta-analysis; Metabolism; Metabolites; Middle Aged; Nicotine; Nicotine - metabolism; NMR; Nuclear magnetic resonance; Pharmacology; Polymorphism, Single Nucleotide; Prevention; Preventive medicine; Psychiatry; Regression analysis; Review boards; Risk; Risk Factors; Single nucleotide polymorphisms; Single-nucleotide polymorphism; Smoking; Smoking Cessation; Studies; Tobacco
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0126113

The Nicotine Metabolite Ratio (NMR, ratio of trans-3'-hydroxycotinine and cotinine), has previously been associated with CYP2A6 activity, response to smoking cessation treatments, and cigarette consumption. We searched for drug metabolizing enzyme and transporter (DMET) gene variation associated with the NMR and prospective abstinence in 2,946 participants of laboratory studies of nicotine metabolism and of clinical trials of smoking cessation therapies. Stage I was a meta-analysis of the association of 507 common single nucleotide polymorphisms (SNPs) at 173 DMET genes with the NMR in 449 participants of two laboratory studies. Nominally significant associations were identified in ten genes after adjustment for intragenic SNPs; CYP2A6 and two CYP2A6 SNPs attained experiment-wide significance adjusted for correlated SNPs (CYP2A6 PACT=4.1E-7, rs4803381 PACT=4.5E-5, rs1137115, PACT=1.2E-3). Stage II was mega-regression analyses of 10 DMET SNPs with pretreatment NMR and prospective abstinence in up to 2,497 participants from eight trials. rs4803381 and rs1137115 SNPs were associated with pretreatment NMR at genome-wide significance. In post-hoc analyses of CYP2A6 SNPs, we observed nominally significant association with: abstinence in one pharmacotherapy arm; cigarette consumption among all trial participants; and lung cancer in four case:control studies. CYP2A6 minor alleles were associated with reduced NMR, CPD, and lung cancer risk. We confirmed the major role that CYP2A6 plays in nicotine metabolism, and made novel findings with respect to genome-wide significance and associations with CPD, abstinence and lung cancer risk. Additional multivariate analyses with patient variables and genetic modeling will improve prediction of nicotine metabolism, disease risk and smoking cessation treatment prognosis.